Sassicaia Capital Advisers LLC Acquires Shares of 12,600 Capricor Therapeutics Inc (NASDAQ:CAPR)

Sassicaia Capital Advisers LLC acquired a new stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPR) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 12,600 shares of the biotechnology company’s stock, valued at approximately $192,000. Capricor Therapeutics makes up 0.6% of Sassicaia Capital Advisers LLC’s investment portfolio, making the stock its 15th biggest position.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Point72 Asset Management L.P. acquired a new stake in Capricor Therapeutics during the third quarter valued at approximately $3,806,000. PFM Health Sciences LP acquired a new stake in Capricor Therapeutics during the third quarter valued at approximately $2,324,000. Fred Alger Management LLC acquired a new stake in Capricor Therapeutics during the third quarter valued at approximately $399,000. BNP Paribas Financial Markets boosted its holdings in shares of Capricor Therapeutics by 868.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 17,699 shares of the biotechnology company’s stock worth $269,000 after acquiring an additional 15,872 shares in the last quarter. Finally, FMR LLC acquired a new position in shares of Capricor Therapeutics in the 3rd quarter worth approximately $370,000. 21.68% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Capricor Therapeutics

In other news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of the stock in a transaction that occurred on Friday, September 20th. The shares were acquired at an average cost of $5.36 per share, for a total transaction of $14,999,997.52. Following the completion of the acquisition, the insider now owns 7,090,351 shares in the company, valued at approximately $38,004,281.36. This represents a 65.21 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 12.00% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Maxim Group boosted their target price on Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, September 25th. Piper Sandler assumed coverage on Capricor Therapeutics in a report on Monday, October 21st. They issued an “overweight” rating and a $35.00 target price on the stock. Oppenheimer reissued an “outperform” rating and issued a $15.00 target price on shares of Capricor Therapeutics in a report on Monday, September 23rd. Cantor Fitzgerald boosted their target price on Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, November 14th. Finally, HC Wainwright reissued a “buy” rating and issued a $77.00 target price on shares of Capricor Therapeutics in a report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $34.50.

Capricor Therapeutics Stock Performance

Shares of CAPR opened at $12.72 on Thursday. Capricor Therapeutics Inc has a 12 month low of $3.09 and a 12 month high of $23.40. The firm has a fifty day simple moving average of $18.50 and a 200 day simple moving average of $9.63.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.